The Use of Mycophenolate Mofetil (Cellcept®) in Renal Transplantation

1998 ◽  
pp. 64-75 ◽  
Author(s):  
Y. Vanrenterghem
Keyword(s):  
Mycophenolate Mofetil ◽  
Renal Transplantation

Review of Major Clinical Trials with Mycophenolate Mofetil in Renal Transplantation

2005 ◽  
Vol 80 (Supplement) ◽  
pp. S191-S200 ◽  
Author(s):  
Gaetano Ciancio ◽  
Joshua Miller ◽  
Thomas A. Gonwa
Keyword(s):  
Clinical Trials ◽  
Mycophenolate Mofetil ◽  
Renal Transplantation

A Randomized Trial With Steroids and Antithymocyte Globulins Comparing Cyclosporine/Azathioprine Versus Tacrolimus/Mycophenolate Mofetil (CATM2) in Renal Transplantation

2012 ◽  
Vol 93 (4) ◽  
pp. 437-443 ◽  
Author(s):  
Henri Vacher-Coponat ◽  
Valerie Moal ◽  
Monica Indreies ◽  
Raj Purgus ◽  
Anderson Loundou ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Renal Transplantation ◽  
Randomized Trial

Albuminuria after renal transplantation: maintenance with sirolimus/low-dose tacrolimus vs. mycophenolate mofetil/high-dose tacrolimus

2010 ◽  
Vol 25 (6) ◽  
pp. 898-904 ◽  
Author(s):  
Clifford D. Miles ◽  
Jill Y. Skorupa ◽  
John P. Sandoz ◽  
Theodore H. Rigley ◽  
Kathleen J. Nielsen ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Renal Transplantation ◽  
Low Dose ◽  
High Dose

Mycophenolate mofetil suppresses the production of anti-blood type anitbodies after renal transplantation across the abo blood barrier: ELISA to detect humoral activity1

2002 ◽  
Vol 74 (8) ◽  
pp. 1187-1189 ◽  
Author(s):  
Hideki Ishida ◽  
Kazunari Tanabe ◽  
Miyuki Furusawa ◽  
Tsutomu Ishizuka ◽  
Hiroaki Shimmura ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Renal Transplantation ◽  
Blood Type

scholarly journals Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil

2005 ◽  
Vol 20 (6) ◽  
pp. 1214-1221 ◽  
Author(s):  
Arun Chandrakantan ◽  
Piti Ratanapanichkich ◽  
Mowaffaq Said ◽  
Catherine V. Barker ◽  
Bruce A. Julian
Keyword(s):  
Mycophenolate Mofetil ◽  
Renal Transplantation ◽  
Iga Nephropathy ◽  
Recurrent Iga Nephropathy

Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients

2004 ◽  
Vol 107 (1) ◽  
pp. 63-68 ◽  
Author(s):  
David GOLDSMITH ◽  
Elizabeth A. CARREY ◽  
Stephen EDBURY ◽  
Ryszard T. SMOLENSKI ◽  
Piotr. JAGODZINSKI ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Renal Transplantation ◽  
Renal Transplant ◽  
Plasma Metabolites ◽  
Renal Transplant Recipients ◽  
Inosine Monophosphate Dehydrogenase ◽  
Inosine Monophosphate ◽  
Transplant Patients ◽  
Renal Transplant Patients ◽  
Monophosphate Dehydrogenase

The immunosuppressant MMF (mycophenolate mofetil) has increasingly replaced AZA (azathioprine) in renal transplantation. MMF is a prodrug of MPA (mycophenolic acid), which inhibits lymphocyte IMPDH (inosine monophosphate dehydrogenase), thereby drastically decreasing GTP concentrations essential to lymphocyte proliferation in vitro and in vivo. Erythrocyte GTP concentrations are commonly elevated in severe renal disease, but normalize following successful engraftment. Consequently, elevated GTP in renal transplant recipients might signal impending loss of immunosuppression and graft failure. In the present study, we compared erythrocyte nucleotides and plasma metabolites in two groups of 25 patients after renal transplantation, both receiving prednisolone and cyclosporin A, but one group receiving MMF and the other AZA. No patients had recent allograft biopsy evidence of rejection. Erythrocyte GTP concentrations at MMF commencement were 50.4±23.4 μmol/l. An increase occurred during the first 3 months after transplant when MMF was used de novo, stabilizing at 146.7±62.9 μmol/l after 4 months. This was significantly higher (P=2.5×10−6) than erythrocyte GTP (40.4±15.9 μmol/l) in the AZA group, which was essentially unchanged from values immediately after successful transplantation. The effect of MMF on erythrocyte GTP levels was reversible, since GTP levels fell when MMF therapy was terminated. The results demonstrate paradoxically high GTP concentrations in erythrocytes of renal transplant patients receiving MMF. MPA may stabilize reticulocyte IMPDH, allowing the protein to persist during erythropoiesis. This behaviour is in marked contrast with the decrease in GTP levels seen in white blood cells of patients on chronic MMF therapy.

Sign in / Sign up

Export Citation Format

Share Document